Research Advances in Resistance to Platinum-based Chemotherapy in Lung Cancer.
10.3881/j.issn.1000-503X.2017.01.025
- Author:
Yajuan ZHANG
1
,
2
;
De CHANG
3
;
Jianpeng ZHANG
3
Author Information
1. Department of Respiratory Medicine,General Hospital of Chinese People's Armed Police Forces,Beijing 100039,China
2. Department of Clinical Medicine,Jinzhou Medical University,Jinzhou,Liaoning 121001,China.
3. Department of Respiratory Medicine,General Hospital of Chinese People's Armed Police Forces,Beijing 100039,China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
pharmacology;
Carcinoma, Non-Small-Cell Lung;
drug therapy;
Drug Resistance, Neoplasm;
Humans;
Lung Neoplasms;
drug therapy;
Platinum;
pharmacology;
Prognosis
- From:
Acta Academiae Medicinae Sinicae
2017;39(1):150-155
- CountryChina
- Language:English
-
Abstract:
Platinum-based chemotherapy is the the cornerstone of treatment of many cancers. Combinations of platinum drugs with other agents are still the mainstream therapies for non-small cell lung cancer,showing significant effectiveness in an early phase. Along with the treatment,the tumor cells can become resistant to chemotherapy drugs,which affect the efficacy and prognosis. The mechanisms of drug resistance are complicated,including abnormal expressions of membrane proteins,enhanced DNA repair functions,abnormal regulation mechanisms of apoptosis,and enhanced cellular detoxification function. In this article we summarize some of the main mechanisms of platinum resistance in lung cancer cells,with an attempt to identify new potential target analogues or inhibitors and improve the efficacies of the combined use of platinum-based drugs.
